Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC)

Required: ESR1 ≤10% expression (≤10%)

Estrogen receptor [ER] ≤10%

Required: PR (PGR) ≤10% expression (≤10%)

Progesterone receptor [PgR] ≤10%

Required: HER2 (ERBB2) HER2-negative as per ASCO/CAP guidelines (negative)

HER2-negative as per ASCO/CAP guidelines

Must have received: systemic chemotherapy — metastatic

Received at least 1 prior line of systemic chemotherapy for metastatic TNBC and/or meet criteria to receive sacituzumab govitecan as standard of care

Cannot have received: anti-GD2 antibody

Have previously received treatment with an anti-GD2 antibody

Cannot have received: TROP2-targeting antibody drug conjugate

Exception: Participants who have received TROP2-targeting antibody drug conjugates in the neoadjuvant setting or adjuvant setting are eligible if at least 6 months have elapsed since the last dose

Prior treatment with TROP2-targeting antibody drug conjugates in the metastatic setting. Participants who have received TROP2-targeting antibody drug conjugates in the neoadjuvant setting or adjuvant setting are eligible if at least 6 months have elapsed since the last dose of TROP2-targeting antibody drug conjugate.